Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib vs Placebo in ES-SCLC Receiving Topotecan
NCT05874401Phase 4Active, not recruiting
- Sponsor
- Pharmacosmos
- Start
- Oct 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Pharmacosmos. Started Oct 2023; status: active, not recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05874401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874401.